The deal will see Repare enter into a worldwide license and collaboration agreement with Roche to develop and commercialize the Montreal company’s drug camonsertib, also known as RP-3500
has struck a deal with pharmaceutical giant F. Hoffman-La Roche AG that could be worth north of US$1-billion to the Canadian startup.
Repare will receive US$125-million upfront from Roche and up to US$1.2-billion if its drug reaches a series of clinical, regulatory, commercial and sales milestones. Repare also stands to earn royalties on sales if the drug makes it to market. Bloom Burton analyst David Martin had nicknamed RP-3500 “the Rodney Dangerfield of oncology drugs” in an April research report, arguing that, like the late comic, the drug “got no respect” despite promising early clinical data from human trials on the drug published in the last year.